Skip to main content
Suma (B) Babu, MD, Neurology, Boston, MA

Suma (B) Babu MD MBBS, MPH (She/Her)

Neuromuscular Medicine, Neurodegenerative


Assistant Professor of Neurology

Join to View Full Profile
  • 55 Fruit StreetBoston, MA 02114

Dr. Babu is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical School
    Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolFellowship, Neurology, 2015 - 2016
  • Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical School
    Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolFellowship, Neuromuscular Medicine (Neurology), 2015 - 2016
  • Cleveland Clinic Foundation
    Cleveland Clinic FoundationResidency, Neurology, 2013 - 2015
  • Cleveland Clinic Foundation
    Cleveland Clinic FoundationInternship, Internal Medicine, 2014 - 2014
  • Cleveland Clinic Foundation
    Cleveland Clinic FoundationFellowship, Child Neurology, 2011 - 2014
  • Cleveland Clinic Foundation
    Cleveland Clinic FoundationResidency, Pediatrics, 2009 - 2011
  • University of Maryland School of Public Health
    University of Maryland School of Public HealthMPH, clinical research, 2006 - 2008
  • Bangalore Medical College
    Bangalore Medical CollegeClass of 2003

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 2015 - 2026
  • ME State Medical License
    ME State Medical License 2021 - 2026
  • NH State Medical License
    NH State Medical License 2022 - 2026
  • OH State Medical License
    OH State Medical License 2009 - 2015
  • Neurology
    American Board of Psychiatry and Neurology Neurology
  • Neuromuscular Medicine
    American Board of Psychiatry and Neurology Neuromuscular Medicine

Publications & Presentations

PubMed

Journal Articles

  • Trial of Sodium Phenylbutyrate–Taurursodiol for Amyotrophic Lateral Sclerosis  
    Sabrina Paganoni, Michael A Elliott, Samuel Maiser, Margaret A Owegi, Stephen A Goutman, Carlayne E Jackson, Jeffrey D Rothstein, Edward J Kasarskis, Liberty Jenkins, ..., The New England Journal of Medicine
  • Integrated Imaging of [11C]-PBR28 PET, MR Diffusion and Magnetic Resonance Spectroscopy 1H-MRS in Amyotrophic Lateral Sclerosis  
    Sabrina Paganoni, Nazem Atassi, Suma Babu, ScienceDirect

Abstracts/Posters

  • Capecitabine Induced Multifocal Leukoencephalopathy: A Case report
    SBabu, LVelander, JVensel-Rundo, American society for Neuroimaging, Las Vegas, Nevada, 1/2013
  • Differences in mouth-level nicotine delivery with variation in cigarette smoke pH
    SBabu, PClark et al, 9 International Joint Conference of SRNT (Society for Research on Nicotine and Tobacco) S, Dublin, Ireland, 4/2009

Lectures

  • Statin Induced Necrotizing Autoimmune Myopathy. Podium presentation at the Neurological Institute Grand Rounds, Cleveland. 
    Cleveland Clinic - 3/2014

Other

  • Menthol Cigarettes: What do we know?” Background paper presented to the World Health Organization 
    Clark.P, Babu.S, Sharma.E, WHO
    11/1/2008

Press Mentions

  • Sean M. Healey & AMG Center Announces Topline Results in HEALEY ALS Platform Trial with eIF2B Agonist DNL343
    Sean M. Healey & AMG Center Announces Topline Results in HEALEY ALS Platform Trial with eIF2B Agonist DNL343January 6th, 2025
  • Sean M. Healey & AMG Center for ALS Announces First Participant Dosed in Regimen G of the HEALEY ALS Platform Trial Evaluating DNL343 by Denali Therapeutics
    Sean M. Healey & AMG Center for ALS Announces First Participant Dosed in Regimen G of the HEALEY ALS Platform Trial Evaluating DNL343 by Denali TherapeuticsJune 8th, 2023

Grant Support

  • An Intermediate-Size Expanded Access Protocol for Amyotrophic Lateral Sclerosis with PridopidineMASSACHUSETTS GENERAL HOSPITAL2023–2027
  • An Intermediate-Size Expanded Access Protocol for Amyotrophic Lateral Sclerosis with PridopidineMASSACHUSETTS GENERAL HOSPITAL2023–2027
  • An Intermediate-Size Expanded Access Protocol for Amyotrophic Lateral Sclerosis with PridopidineMASSACHUSETTS GENERAL HOSPITAL2023–2027
  • Intermediate-Size Expanded Access Trial of Autologous Hybrid TREG/Th2 Cell Therapy (RAPA-501) of Amyotrophic Lateral SclerosisMASSACHUSETTS GENERAL HOSPITAL2023–2026
  • Intermediate-Size Expanded Access Trial of Autologous Hybrid TREG/Th2 Cell Therapy (RAPA-501) of Amyotrophic Lateral SclerosisMASSACHUSETTS GENERAL HOSPITAL2023–2026
  • Intermediate-Size Expanded Access Trial of Autologous Hybrid TREG/Th2 Cell Therapy (RAPA-501) of Amyotrophic Lateral SclerosisMASSACHUSETTS GENERAL HOSPITAL2023–2026
  • Intermediate-Size Expanded Access Trial of Autologous Hybrid TREG/Th2 Cell Therapy (RAPA-501) of Amyotrophic Lateral SclerosisMASSACHUSETTS GENERAL HOSPITAL2023–2026
  • Access for All in ALS (ALL ALS) East Clinical Coordinating CenterMASSACHUSETTS GENERAL HOSPITAL2023–2025
  • Access for All in ALS (ALL ALS) East Clinical Coordinating CenterMASSACHUSETTS GENERAL HOSPITAL2023–2025
  • Access for All in ALS (ALL ALS) East Clinical Coordinating CenterMASSACHUSETTS GENERAL HOSPITAL2023–2025
  • Access for All in ALS (ALL ALS) East Clinical Coordinating CenterMASSACHUSETTS GENERAL HOSPITAL2023–2025
  • An Expanded Access Protocol of Intravenous Trehalose Injection 90 mg/mL Treatment of Patients with Amyotrophic Lateral SclerosisMASSACHUSETTS GENERAL HOSPITAL2022–2025

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: